SCHEMBL8212993

SCHEMBL8212993

CC(=O)Nc1cn2cc(-c3cncc(NS(C)(=O)=O)c3)ccc2n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 12/20 0.54
PIK3CD O00329 3/20 0.53
PIK3CG P48736 3/20 0.53
PIK3C3 Q8NEB9 2/20 0.53
PIK3CB P42338 2/20 0.53
PI4KB Q9UBF8 1/20 0.53
AKT1 P31749 1/20 0.53
MTOR P42345 1/20 0.53
PIP4K2A P48426 4/20 0.52
PIP4K2B P78356 4/20 0.52
MAPK13 O15264 1/20 0.47
BRAF P15056 1/20 0.47
KDR P35968 1/20 0.47
MAPK12 P53778 1/20 0.47
MAPK11 Q15759 1/20 0.47
MAPK14 Q16539 1/20 0.47
MAP3K5 Q99683 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3711646 0.88 PIK3CA (0.52) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL8214637 0.87 PIK3CA (0.60) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL3128211 0.87 PIK3CA (0.50) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL8216906 0.85 PIK3CA (0.71) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL13188706 0.85 PIK3CA (0.66) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL3711642 0.82 PIK3CA (0.53) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL2946432 0.81 PIK3CA (0.65) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL13188708 0.80 PIK3C3 (0.61) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB
SCHEMBL13154322 0.80 PIK3CG (0.76) PIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL3252983 0.80 PIK3CA (0.55) PIK3CAPIK3CDPIK3CGPIK3C3PIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820665-B2 Imidazopyridazine inhibitors of PI3 kinase for cancer treatment AMGEN INC. (US) 2010-10-26 US disclosed
US-7820665-B2 Imidazopyridazine inhibitors of PI3 kinase for cancer treatment AMGEN INC. (US) 2010-10-26 US disclosed
WO-2010100144-A1 FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE MERCK SERONO S.A. (CH) 2010-09-10 WO disclosed
WO-2009085230-A1 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-07-09 WO disclosed
US-20090163489-A1 Inhibitors of PI3 kinase AMGEN INC. 2009-06-25 US disclosed
US-20090163489-A1 Inhibitors of PI3 kinase AMGEN INC. 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163489-A1 Inhibitors of PI3 kinase PIK3CA, PIK3CD, PIK3CG PIK3CA 1/4885PIK3CD 2/4885PIK3CG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.